Pharming Group (NASDAQ:PHAR – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15, FiscalAI reports. The business had revenue of $117.60 million during the quarter, compared to analysts’ expectations of $117.60 million. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.
Pharming Group Stock Performance
Shares of Pharming Group stock opened at $11.90 on Tuesday. Pharming Group has a 52 week low of $9.11 and a 52 week high of $21.34. The business’s fifty day simple moving average is $10.69 and its 200-day simple moving average is $13.92. The firm has a market cap of $842.28 million, a PE ratio of 99.17 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, September 22nd. Wall Street Zen upgraded Pharming Group to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a research note on Friday, August 7th. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Finally, Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $38.67.
Read Our Latest Stock Report on PHAR
About Pharming Group
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.
Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
Recommended Stories
- Five stocks we like better than Pharming Group
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
